Yimin Shi

Dr. Yimin Shi


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2022 in American Journal of Reproductive Immunology
Verified
Journal Article
Open access
YSYimin Shi
Yimin Shi
DTDongmei Tan
Dongmei Tan
BHBaozhen Hao
Baozhen Hao
XZXiurong Zhang
Xiurong Zhang
WGWei Geng
Wei Geng
YZYue Zhao
Yue Zhao
Objective: We aimed to evaluate the efficacy of IVIG in the treatment with patients with recurrent spontaneous abortion (RSA).Methods: PubMed, Embase, Web of science, Cochrane library were searched for randomized controlled (RCTs) about effect of IVIG on RSA from inception to August 20, 2021. Values of standardized mean differences (SMD) were determined for continuous outcomes.Results: A total of 15 articles involving 902 patients were included in meta‐analysis. Compared with the control group, IVIG can increase the live birth rate of recurrent spontaneous abortion patients [OR = 3.06, 95%CI (1.23, 7.64, P = .02]. However, recurrent abortion was divided into primary and secondary abortion for subgroup analysis, and there was no statistical difference. Besides, IVIG can also increase the expression in peripheral blood CD3+[OR = .4, 95%CI(‐2.47, 3.15, P = .81],CD4+[OR = 1.16, 95%CI(‐4.60, 6.93, P = .69], and a decrease in the expression of CD8+[OR = ‐1.78, 95%CI(‐5.30, 1.75, P = .32], but there is no statistical significance.Conclusions: IVIG can significantly increase the live birth rate of recurrent spontaneous abortion. However, the evidence needs further verification and the curative effect is uncertain. It is necessary to further explore the pathogenesis of recurrent abortion and the mechanism of IVIG in the treatment of recurrent spontaneous abortion. Besides, more high‐quality randomized controlled trials suitable for population, race, dosage and timing of IVIG in the treatment of recurrent abortion are needed to confirm its effectiveness, and effective systematic evaluation is also needed to evaluate its use benefit.

6 September 2024 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
QMQian Ma
Qian Ma
YSYimin Shi
Yimin Shi
WZWei Zhao
Wei Zhao
HZHuixiang Zhang
Huixiang Zhang
DTDongmei Tan
Dongmei Tan
LLLin Liu
Lin Liu
To assess the effectiveness of Internet-based self-help interventions in treating depression in adolescents and young adults. A systematic search was conducted across six databases, including PubMed, to identify randomized controlled trials (RCTs) that satisfied the specified inclusion and exclusion criteria. The intervention measure consisted of Internet-based self-help interventions. A total of 23 randomized controlled trials (RCTs) were included in this analysis. Meta-analysis indicated that Internet-based self-help therapies significantly reduced depression scores in adolescents and young adults. (OR = -0.68, 95%CI [-0.88, -0.47], P < 0.001). We examined the effects of patient recruitment from various regions, medication usage, therapist involvement, weekly intervention time, and intervention duration. Patients selected from school, primary healthcare centers, clinics and local communities had better results. Intervention lasting 30 to 60 min and 60 to180 minutes per week were effective in the short term. The internet-based self-help intervention can be effective in treating depression in adolescents and young adults. However, factors such as patient recruitment locations, medication usage, Therapists’ involvement, weekly intervention time, and intervention duration interacted with the outcome. Subgroup analysis on potential adverse effects and gender was impossible due to insufficient data from the included studies.

1 June 2003 in Biochemical Pharmacology
Verified
Journal Article
Closed access
CZChenyang zhao
Chenyang zhao
YSYimin Shi
Yimin Shi
WWWenfeng Wang
Wenfeng Wang
ZJZhongjian Jia
Zhongjian Jia
SYSide Yao
Side Yao
RZRongliang Zheng
Rongliang Zheng

1 October 1999 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
YSYimin Shi
Yimin Shi
JKJiuhong Kang
Jiuhong Kang
WLWeizheng Lin
Weizheng Lin
PFPotao Fan
Potao Fan
ZJZhongjian Jia
Zhongjian Jia
RZRongliang Zheng
Rongliang Zheng

28 June 2022 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
JXJiayi Xu
Jiayi Xu
XSXiaomeng Shan
Xiaomeng Shan
CCChunwei Chen
Chunwei Chen
YGYanbin Gao
Yanbin Gao
DZDawei Zou
Dawei Zou
YSYimin Shi
Yimin Shi
Diabetic nephropathy (DN) is a microvascular complication of diabetes mellitus (DM) and the most common cause of death in diabetic patients. DN progression is associated with podocyte damage due to reduced autophagy caused by mTORC1 activation. Tangshenning (TSN) has been shown to reduce proteinuria, protect renal function, and reduce podocyte damage. Still, the effect of TSN on the autophagic activity of podocytes remains unclear. Herein, in vitro experiments using a high glucose-induced podocyte injury model were performed. Results showed that TSN treatment enhanced the weakened nephrin expression and autophagic activity of podocytes and inhibited the mTORC1 pathway (p-mTOR, mTOR, p-p70S6K, p70S6K, ULK1, and 4EBP1) under high glucose conditions. Furthermore, the mTORC1 activator (siRNA-TSC2) partially inhibited the above beneficial effects of TSN, suggesting that mTORC1 was the target of TSN to regulate autophagy. In summary, TSN reduces podocyte damage induced by high glucose via inhibiting mTORC1 pathway and downstream targets and restoring podocyte autophagy.

17 March 2026 in Clinical and Experimental Obstetrics & Gynecology
Verified
Journal Article
Open access
DTDongmei Tan
Dongmei Tan
YSYimin Shi
Yimin Shi
XKXinliang Kong
Xinliang Kong
PCPingping Cai
Pingping Cai
ZMZhaoqing Meng
Zhaoqing Meng
Objective: This review summarizes global advances in antibody-drug conjugate (ADC) research for the treatment of gynecologic cancers and highlights China’s rapidly evolving role in developing these agents, aiming to contextualize their growing impact on future therapeutic standards. Mechanism: ADCs represent a transformative class of targeted therapies, coupling monoclonal antibodies with potent cytotoxic payloads through linkers, thereby enabling selective drug delivery to tumor cells while minimizing systemic toxicity. Findings in Brief: Globally, ADCs such as mirvetuximab soravtansine and tisotumab vedotin have demonstrated significant clinical benefits in platinum-resistant ovarian and recurrent cervical cancers. Parallel progress in other ADCs has expanded therapeutic options across ovarian, endometrial, and cervical cancers. In China, ADC development is accelerating, with several domestically developed agents targeting folate receptor alpha, human epidermal growth factor receptor 2, trophoblast cell surface antigen 2, cadherin-6, nectin-4, B7 homolog 4, and epidermal growth factor receptor/human epidermal growth factor receptor 3 advancing into phase II and III trials. Early results show encouraging efficacy and safety, underscoring China’s emergence as a key contributor to global anticancer innovation. Nevertheless, variability in biomarker assay, regulatory differences, and future challenges related to pricing and equitable access remain important considerations. Conclusions: ADCs are redefining the treatment landscape for gynecologic cancers. China’s expanding pipeline, supported by domestic innovation and international collaboration, is poised to significantly influence future standards of care. Continued progress in clinical validation, regulatory alignment, and the development of diagnostic and reimbursement infrastructures will be essential to ensure that these novel therapies achieve meaningful and equitable global impact.